Table 1.
Characteristic of patients in the overall study population and in patients stratified in survivors and non survivors.
| All (n=257) | Survivors (n=126) | Non Survivors (n=131) | p value | |
|---|---|---|---|---|
| Age, y | 70.5±10.7 | 67.3±10.5 | 73.6±9.9 | <0.0001 |
| Gender, % Male (n) | 71.6 (184) | 74.6 (94) | 68.7 (90) | 0.29 |
| LVEF, % | 31.4±8.5 | 35.5±7.4 | 27.5±7.6 | <0.0001 |
| NYHA class, % (n) | II = 18.3 (47) III = 81.7 (210) |
II = 25.4 (32) III = 74.6 (94) |
II = 11.5 (15) III = 88.5 (116) |
0.004 |
| SBP (mmHg) | 132.1±15.2 | 130.6±16.4 | 133.7±14.0 | 0.11 |
| Resting HR (bpm) | 73.5±9.6 | 73.1±10.1 | 73.9±9.2 | 0.48 |
| LBBB, % (n) | 14.0 (36) | 13.5 (17) | 14.5 (19) | 0.92 |
| Low serum sodium (<130 meq/L), % (n) | 15.9 (41) | 15.8 (20) | 16.0 (21) | 0.972 |
| Low serum cholesterol (<130 mg mg/dL), % (n) | 8.5 (22) | 8.7 (11) | 8.3 (11) | 0.7 |
| Hyperuricemia (>9.5 mg/dL), % (n) | 21.7 (56) | 21.4 (27) | 22.1 (29) | 0.89 |
| Comorbidity | ||||
| Hypertension, % (n) | 76.3% (196) | 77.0% (97) | 75.6% (99) | 0.88 |
| Diabetes, % (n) | 45.1% (116) | 38.9% (49) | 51.1% (67) | 0.03 |
| COPD, % (n) | 29.2% (75) | 27.0% (34) | 31.3% (41) | 0.49 |
| GFR <50 ml/mg, % (n) | 35.8% (92) | 25.4% (32) | 45.8% (60) | 0.001 |
| Drugs | ||||
| ACE I / ARBs, % (n) | 82.1% (211) | 81.0% (102) | 83.2% (109) | 0.75 |
| BetaBlockers, % (n) | 51.8% (133) | 54.8% (69) | 48.9% (64) | 0.38 |
| Biochemical determinations | ||||
| Serum NT-proBNP*, pg/dl | 1310±852 (1169/664-1767) | 868±567 (809/425-1191) | 1736±864 (1642/1028-2295) | <0.0001 |
| Plasma Norepinephrine*, pg/dl | 606.7±246.4 (624/391-763) | 551.7±227.3 (547/377-709) | 659.5±253.3 (684/491-824) | <0.0001 |
| Lymphocyte GRK2*, D.U. | 1.42±0.71 (1,31/0.89-1.74) | 1.17±0.62 (1,01/0.77-1.52) | 1.66±0.71 (1,6/1.23-1.89) | <0.0001 |
Normally distributed variables are expressed as mean±SD, binary data as percentage and not normally distributed variables(*) are expressed as mean±SD (median/interquartile range value). LVEF= left ventricular ejection fraction; NYHA= New York Heart Association; COPD= chronic obstructive pulmonary disease; GFR= Glomerural Filtration Rate; ACE I= angiotensin-converting-enzyme inhibitor; ARBs= angiotensin receptor blockers; NT-proBNP= N-terminal pro-brain natriuretic peptide; GRK2= G coupled-receptor Kinase. P value refers to the survivors/non-survivors comparisons; LBBB= left bundle branch block.